<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The AML1 gene encodes a DNA-binding protein that contains the <z:mp ids='MP_0001265'>runt</z:mp> domain and is the most frequent target of translocations associated with human <z:hpo ids='HP_0001909'>leukemias</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Here, point mutations of the AML1 gene, V105ter (single-letter amino acid code) and R139G, (single-letter amino acid codes) were identified in 2 cases of <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) by means of the reverse transcriptase-polymerase chain reaction single-strand conformation polymorphism method </plain></SENT>
<SENT sid="2" pm="."><plain>Both mutations are present in the region encoding the <z:mp ids='MP_0001265'>runt</z:mp> domain of AML1 and cause loss of the DNA-binding ability of the resultant products </plain></SENT>
<SENT sid="3" pm="."><plain>Of these mutants, V105ter has also lost the ability to heterodimerize with polyomavirus enhancer binding protein 2/core binding factor beta (PEBP2beta/CBFbeta) </plain></SENT>
<SENT sid="4" pm="."><plain>On the other hand, the R139G mutant acts as a dominant negative inhibitor by competing with <z:mp ids='MP_0002169'>wild-type</z:mp> AML1 for interaction with PEBP2beta/CBFbeta </plain></SENT>
<SENT sid="5" pm="."><plain>This study is the first report that describes mutations of AML1 in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and the mechanism whereby the mutant acts as a dominant negative inhibitor of <z:mp ids='MP_0002169'>wild-type</z:mp> AML1 </plain></SENT>
</text></document>